Novavax Inc. ($NVAX) Stock Forecast: Down 5.4% Today

What is Novavax Inc.?

Novavax (NVAX) is a pharmaceutical company renowned for its vaccine development, including for COVID-19. The stock had a bearish movement today, closing at $8.90 with a 1.17% drop, underperforming both the Medical sector and the S&P 500.

Why is Novavax Inc. going down?

NVAX stock is down 5.4% on Jun 25, 2026 14:46

• Novavax's stock experienced a larger drop than the general market, reflecting investor concerns and lack of confidence in the company's performance.
• Criticism from activist investor Shah Capital following the annual meeting has added pressure on Novavax, highlighting shareholder dissatisfaction with executive compensation and board decisions.
• Anticipation of the upcoming earnings report, expected to show significant year-over-year declines in earnings and revenue, has further dampened investor sentiment.
• The stock's underperformance compared to competitors and the broader market trends indicates a challenging environment for Novavax, requiring strategic changes to regain investor trust and improve shareholder value.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights

Novavax (NVAX) closed at $8.90, experiencing a 1.17% drop that outpaced the S&P 500's loss. Over the past month, the stock has fallen 13.96%, significantly underperforming the Medical sector and S&P 500. Analysts anticipate a substantial year-over-year decline in Novavax's upcoming earnings and revenue.

https://finance.yahoo.com/markets/stocks/articles/novavax-nvax-suffers-larger-drop-214503542.html

Shah Capital blasts Novavax annual meeting results

Activist investor Shah Capital has sharply criticized the results of Novavax's 2026 annual general meeting, highlighting significant shareholder dissatisfaction despite the proposals passing. The criticism focused on strong opposition to executive compensation and the re-election of Class I directors, which Shah Capital views as a "wake-up call" for Novavax's leadership regarding performance, costs, and shareholder value destruction. Shah Capital reiterated its calls for change, including a smaller board, a more pragmatic business strategy, and share repurchases.

https://americanbazaaronline.com/2026/06/24/shah-capital-blasts-novavax-annual-meeting-results-483458/

Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights

Novavax (NVAX) experienced a larger drop than the general market, closing down 1.17% while the S&P 500 lost 0.1%. The vaccine maker's stock has also fallen by 13.96% over the past month, underperforming the Medical sector. Investors are anticipating the upcoming earnings report, which is projected to show significant year-over-year declines in EPS and revenue.

https://ca.finance.yahoo.com/news/novavax-nvax-suffers-larger-drop-214503542.html

Novavax Draws Fresh Criticism From Largest Shareholder Shah Capital Following Annual Meeting

Novavax Inc. is facing renewed criticism from its largest shareholder, Shah Capital, despite all proposals passing at its recent annual meeting. Shah Capital highlighted significant shareholder dissatisfaction, with 38% to 41% of votes opposing Class I directors, including the CEO, calling the opposition "unprecedented." The hedge fund continues to advocate for board changes, cost-cutting, and a share repurchase program.

https://www.citybiz.co/article/865350/novavax-draws-fresh-criticism-from-largest-shareholder-shah-capital-following-annual-meeting/

Novavax Inc. stock underperforms Wednesday when compared to competitors

Novavax Inc.'s stock (NVAX) fell by 1.11% on Wednesday, closing at $8.90, even as the Dow Jones Industrial Average rose. The company's shares are now 25.65% below their 52-week high of $11.97. This performance indicates an underperformance compared to the broader market trends on that day.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-wednesday-when-compared-to-competitors-2018e49d-d86b5b5ce338?mod=mw_quote_news

Trending Today

Gasoline ($GASOLINE) Commodity Forecast: Up 5.0% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 5.1% Today

Wingstop Inc. ($WING) Stock Forecast: Up 5.4% Today

Nasdaq Inc. ($NDAQ) Stock Forecast: Down 5.1% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Down 5.3% Today

MSCI Inc ($MSCI) Stock Forecast: Down 5.8% Today

Ross Stores Inc. ($ROST) Stock Forecast: Down 5.2% Today

Caterpillar Inc. ($CAT) Stock Forecast: Up 6.2% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Down 5.9% Today

TJX Companies Inc. (The) ($TJX) Stock Forecast: Down 5.8% Today

Novavax Inc. Price History

28.04.2026 - NVAX Stock was down 9.9%

• Despite recent insider selling by Ruxandra Draghia Akli, Novavax Inc. experienced a strong bearish movement today.
• The stock had been performing well in the past few days, outperforming competitors and showing consecutive gains.
• However, the stock closed significantly below its 52-week high, indicating some profit-taking by investors.
• The mixed trading day in the market, along with profit-taking and potential concerns about insider selling, might have contributed to the bearish movement in Novavax's stock price today.

26.04.2026 - NVAX Stock was up 6.3%

• Novavax Inc. (NVAX) stock outperformed its competitors and major indices like the NASDAQ Composite and Dow Jones Industrial Average, showcasing resilience and strength in its market position.
• The fluctuation in Novavax's stock price can be attributed to its operating margin percentage, indicating potential financial health and operational efficiency improvements.
• Despite a recent decline, Novavax bounced back with a 4.16% increase, breaking a losing streak and demonstrating investor confidence in the company's future prospects.
• Overall, Novavax's stock movement today reflects both internal financial metrics and broader market trends, positioning the company as a key player in the biotechnology sector with promising growth potential.

29.04.2026 - NVAX Stock was up 5.4%

• Despite a favorable market environment yesterday, Novavax Inc. lagged behind its competitors, possibly due to profit-taking following a recent winning streak.
• The sale of 30,000 NVAX shares by an insider initially sparked some market uncertainty, but its overall impact was neutral, indicating a limited influence on the stock's upward trend.
• Novavax's consistent gains and outperformance relative to its peers reflect positive market sentiment and strong trading sessions driving the surge in the stock.
• While not directly linked to stock movement, Novavax's operating margin percentage in financial data may offer insights into the company's financial well-being and future growth prospects. This factor enhances investor confidence and bolsters the bullish momentum.

05.05.2026 - NVAX Stock was down 5.7%

• Novavax Inc. (NVAX) saw a decline in its stock price for the second day in a row, despite overall market gains.
• Investor worries may have been exacerbated by a looming deadline in a legal case accusing the company of making misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline.
• Participation in a healthcare conference did not have a positive impact on Novavax's stock performance.
• The stock's lag behind competitors and its 52-week high have contributed to the prevailing negative investor sentiment towards Novavax Inc., causing a downward trend in the market.

08.05.2026 - NVAX Stock was down 7.4%

• Despite recent positive sentiment, Novavax (NVAX) saw a significant 6.87% drop in its shares, performing below market expectations.
• The decline may be linked to profit-taking following a 10.4% surge post-earnings report, prompting investors to review their holdings.
• While early COVID-19 vaccine trials and analyst enthusiasm initially drove the stock up, market realities and profit concerns likely led to the recent downturn.
• Investors are advised to keep an eye on forthcoming clinical trial outcomes and market conditions for a clearer picture of the stock's future trajectory.

08.05.2026 - NVAX Stock was down 5.3%

• The bearish movement in NVAX's stock price can be attributed to a combination of factors:
• The underperformance compared to competitors and broader market indices on multiple consecutive days indicates a lack of investor confidence in the company's current financial performance and growth prospects.
• The looming deadline for investors to file in a securities class action lawsuit alleging misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline could be adding further downward pressure on the stock.
• Despite bullish sentiments from some traders based on technical analysis and ongoing vaccine trials, the negative news surrounding the lawsuit and consistent stock underperformance seem to be overshadowing any positive momentum.
• Overall, the market sentiment towards NVAX appears cautious and uncertain, with investors closely monitoring both the company's financial results and legal developments.

11.05.2026 - NVAX Stock was up 5.2%

• Despite a series of consecutive declines in recent sessions, Novavax (NVAX) experienced a strong bullish movement today.
• The company's shift to a royalty-based model and concerns regarding limited growth potential had impacted NVAX shares negatively in the past.
• AI-generated trading strategies that emphasized in an analysis may have attracted investors seeking favorable risk-reward scenarios, potentially contributing to the bullish movement.
• There is a possibility that investors are reevaluating the company's profitability and long-term outlook, which could explain the positive market movement for Novavax today.

27.04.2026 - NVAX Stock was up 10.2%

• NVAX stock surged by 13.57% to $10.46, marking the second consecutive day of gains, showcasing strong investor confidence in the company's future prospects.
• The positive market movement could be attributed to the company's promising vaccine development pipeline and potential breakthroughs in the fight against infectious diseases.
• Despite fluctuations in the broader market, NVAX's consistent outperformance indicates a favorable sentiment towards the company's innovative approach and growth potential.
• Investors seem optimistic about NVAX's ability to capitalize on the increasing demand for vaccines, driving the stock price higher amidst a volatile market environment.

17.05.2026 - NVAX Stock was up 5.5%

• The bullish movement in Novavax Inc. (NVAX) today can be attributed to several factors:
• After a weaker performance on Friday, the stock showed a strong rebound today, surpassing both competitors and the broader market.
• Positive developments within the company, like progress in vaccine research or encouraging clinical trial results, likely increased investor confidence.
• Insights shared by Novavax executives at the Bank of America Global Healthcare Conference were received positively by analysts and investors, suggesting a promising future outlook for the company.
• The overall market sentiment and momentum also played a role in the bullish movement, as investors explored opportunities in the healthcare sector on a positive trading day.

02.05.2026 - NVAX Stock was down 6.2%

• Novavax recently took part in the 2026 Jefferies Global Healthcare Conference to showcase its vaccine technology platform. However, this did not translate into a positive market response for the stock.
• Despite a generally favorable trading day for the broader market, Novavax's stock performed worse than its competitors, closing 4.19% lower.
• AI-driven liquidity mapping analysis for NVAX suggested strong sentiment and potential upside, yet the stock still faced a bearish trend.
• The stock closed below its 52-week high, signaling potential investor concerns about the company's growth prospects or market conditions, contributing to the bearish movement.

02.05.2026 - NVAX Stock was down 5.1%

• NVAX stock experienced a downtrend today, potentially due to the approaching deadline for investors to join a securities class action lawsuit. This lawsuit alleges misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline, resulting in significant financial setbacks.
• Despite participation in a recent conference to discuss its vaccine technology platform, the negative impact of the pending lawsuit appears to have overshadowed any positive developments for the company.
• NVAX stock's underperformance relative to its peers, despite overall positive market conditions, indicates that investor sentiment may be more influenced by legal uncertainties than company-specific news or market trends.
• The stock showed some improvement on a strong trading day, surpassing the broader market. However, it still closed below its 52-week high, suggesting ongoing concerns related to the lawsuit are impacting investor confidence in Novavax's future prospects.

25.05.2026 - NVAX Stock was down 5.4%

• Novavax's stock experienced a larger drop than the general market, reflecting investor concerns and lack of confidence in the company's performance.
• Criticism from activist investor Shah Capital following the annual meeting has added pressure on Novavax, highlighting shareholder dissatisfaction with executive compensation and board decisions.
• Anticipation of the upcoming earnings report, expected to show significant year-over-year declines in earnings and revenue, has further dampened investor sentiment.
• The stock's underperformance compared to competitors and the broader market trends indicates a challenging environment for Novavax, requiring strategic changes to regain investor trust and improve shareholder value.